NITRIC OXIDE

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	NO
Molecular Weight	30.0061
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[N]=O

InChI

InChIKey=ODUCDPQEXGNKDN-UHFFFAOYSA-N

InChI=1S/HNO/c1-2/h1H

HIDE SMILES / InChI

Molecular Formula	NO
Molecular Weight	30.0061
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19538173https://www.drugs.com/pro/sodium-nitroprusside.html | https://www.ncbi.nlm.nih.gov/pubmed/7598246https://www.ncbi.nlm.nih.gov/pubmed/8644642 | https://www.ncbi.nlm.nih.gov/pubmed/7504768 | https://www.ncbi.nlm.nih.gov/pubmed/1724528 | https://adisinsight.springer.com/drugs/800001151https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19601018&CC=US&NR=2957021A&KC=A | https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20020124&CC=WO&NR=0205795A2&KC=A2http://www.ncbi.nlm.nih.gov/pubmed/6985697https://www.ncbi.nlm.nih.gov/pubmed/13426891 | https://www.ncbi.nlm.nih.gov/pubmed/13284675http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021134s004lbl.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/19732062 | https://www.ncbi.nlm.nih.gov/pubmed/28988245 | https://www.ncbi.nlm.nih.gov/pubmed/24923291 | https://www.ncbi.nlm.nih.gov/pubmed/19563531https://adisinsight.springer.com/drugs/800005482 | https://www.ncbi.nlm.nih.gov/pubmed/9845803http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020845s016s017lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020215s024lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019790s011lbl.pdfwww.ncbi.nlm.nih.gov/pubmed/24071762
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/13106442

Pentaerythritol tetranitrate is an organic nitrate that has been used for the treatment of angina pectoris. Upon administration, the drug undergoes exstensive metabolism to NO which causes vasodilation and the relaxation of smooth muscle cells. The compound belongs to a familiy of explosive substances and may be used accordingly.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
liberation of NO 20 Target ID: liberation of NO Sources: http://www.ncbi.nlm.nih.gov/pubmed/2242448	Activator 1447
Soluble guanylate cyclase 36 Target ID: CHEMBL2111348 Sources: www.ncbi.nlm.nih.gov/pubmed/18574453	Activator 1447	0.1 µM [EC50]
nitric oxide mediated signal transduction 20 Target ID: GO:0007263 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23927471	Activator 1447
Soluble guanylate cyclase 36 Target ID: CHEMBL2111348 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24560804	Activator 1447
Atrial natriuretic peptide receptor A 21 Target ID: CHEMBL1988 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12419094	Activator 1447
Soluble guanylate cyclase 36 Target ID: CHEMBL2111348 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10553632	Activator 1447
Soluble guanylate cyclase 36 Target ID: CHEMBL2111348 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021134s004lbl.pdf	Activator 1447
Soluble guanylate cyclase 36 Target ID: CHEMBL2111348 Sources: https://www.google.com/patents/EP2805730A1	Activator 1447

Conditions

Condition	Modality	Highest Phase	Product
Cancer 609 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12700285	Primary	Preclinical	Unknown Approved Use Unknown
Hypertensive crises 20 Sources: https://www.drugs.com/pro/sodium-nitroprusside.html#s-34067-9	Primary	Approved 8583	NIPRIDE Approved Use Sodium Nitroprusside injection is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with Sodium Nitroprusside can be minimized. Sodium Nitroprusside injection is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium Nitroprusside injection is also indicated for the treatment of acute congestive heart failure. Launch Date 1974
Heart failure 106 Sources: https://www.drugs.com/pro/sodium-nitroprusside.html#s-34067-9	Primary	Approved 8583	NIPRIDE Approved Use Sodium Nitroprusside injection is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with Sodium Nitroprusside can be minimized. Sodium Nitroprusside injection is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium Nitroprusside injection is also indicated for the treatment of acute congestive heart failure. Launch Date 1974
Pulmonary hypertension 32 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020845s016s017lbl.pdf	Palliative	Approved 8583	INOMAX Approved Use INOmax is a vasodilator indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. Launch Date 1999
Angina pectoris 110 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019790s011lbl.pdf	Primary	Approved 8583	DILATRATE-SR Approved Use dilatrate®-SR sustained release capsules are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of controlled-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. Launch Date 1998
Angina pectoris 110 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020215s024lbl.pdf	Primary	Approved 8583	MONOKET Approved Use monoket® is indicated for the prevention and treatment of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. Launch Date 1993
Angina pectoris 110 Sources: http://www.ncbi.nlm.nih.gov/pubmed/16644612	Primary	Approved 8583	Unknown Approved Use Unknown
Coronary heart disease 43 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2242448	Primary	Basic research	Unknown Approved Use Unknown
Angina 34 Sources: https://www.drugs.com/monograph/nitroglycerin.html	Primary	Approved 8583	NITROSTAT Approved Use Acute relief of angina pectoris secondary to CAD; acute prophylactic management in situations likely to provoke angina attacks; and long-term prophylactic management of angina pectoris. Launch Date 2000
Myocardial infarction 125 Sources: https://www.drugs.com/monograph/nitroglycerin.html	Primary	Approved 8583	NITROGLYCERIN Approved Use Management of patients with acute myocardial infarction (MI). Nitroglycerin is one of the principal initial therapies of MI. Launch Date 1981
Hypertension 575 Sources: https://www.drugs.com/monograph/nitroglycerin.html	Primary	Approved 8583	NITROGLYCERIN Approved Use IV nitroglycerin is used to control BP in perioperative hypertension, especially hypertension associated with cardiovascular procedures; to control BP in patients with severe hypertension† or in hypertensive crises for the immediate reduction of BP in patients in whom such reduction is considered an emergency (hypertensive emergencies), especially those associated with coronary complications (e.g., coronary ischemia, acute coronary insufficiency, acute left ventricular failure, postoperative hypertension [especially following coronary bypass surgery]); and to produce controlled hypotension during surgical procedures. Launch Date 1981
Heart failure 106 Sources: https://www.drugs.com/monograph/nitroglycerin.html	Primary	Approved 8583	NITROGLYCERIN Approved Use IV nitroglycerin has been used in the management of acutely decompensated (e.g., congestive) heart failure and other low cardiac-output states. Launch Date 1981
Angina pectoris 110 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4284102 https://www.ncbi.nlm.nih.gov/pubmed/13271134 https://www.ncbi.nlm.nih.gov/pubmed/13426891 https://www.ncbi.nlm.nih.gov/pubmed/13284675	Primary	Approved 8583	Metamine Approved Use https://www.ncbi.nlm.nih.gov/pubmed/13426891 \| https://www.ncbi.nlm.nih.gov/pubmed/13284675
Angina pectoris 110 Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1952976/pdf/brmedj02877-0002.pdf	Primary	Approved 8583	PERITRATE Approved Use Unknown

C_max

Value	Dose	Analyte	Population
187 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24851040	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	ISOSORBIDE DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
356 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/	20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
388 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
557 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1151 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/	120 mg 1 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
84 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/	13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered:	GLYCERYL 1,2-DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.7 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208424s000lbl.pdf	800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered:	NITROGLYCERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
17 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PENTAERYTHRITOL DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
7.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PENTAERYTHRITOL DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
79 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PENTAERYTHRITOL MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
35 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PENTAERYTHRITOL MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
15 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3838399/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
29.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
17.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.89 ng/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.03 ng/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.26 ng/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.08 ng/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
32 μg/L EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
37 μg/L EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg 1 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8 μg/L EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8 μg/L EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg 1 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
32 μg/L EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
34 μg/L EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
8 μg/L EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10 μg/L EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Analyte	Population
1458 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24851040	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	ISOSORBIDE DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2647 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/	20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2524 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6979 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
14241 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/	120 mg 1 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3380 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/	13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered:	GLYCERYL 1,2-DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
12.3 pg × min/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208424s000lbl.pdf	800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered:	NITROGLYCERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
106.5 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
31.7 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
12.2 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7.4 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
17.54 ng × h/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.5 ng × h/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.46 ng × h/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.11 ng × h/mL/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
311 ng × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
423 ng × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg 1 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
60 ng × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
61 ng × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg 1 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
335 ng × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
310 ng × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
49 ng × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
70 ng × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
303 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24851040	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	ISOSORBIDE DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/	20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/	120 mg 1 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ISOSORBIDE MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
50 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/	13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered:	GLYCERYL 1,2-DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
40 min DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208424s000lbl.pdf	800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered:	NITROGLYCERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2 min REVIEW https://pubmed.ncbi.nlm.nih.gov/6375932/	single, intravenous	NITROPRUSSIDE plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PENTAERYTHRITOL DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PENTAERYTHRITOL DINITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PENTAERYTHRITOL MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PENTAERYTHRITOL MONONITRATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3838399/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1955198/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
13.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1777378/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
12 h EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12 h EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg 1 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10 h EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12 h EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg 1 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9.7 h EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8.2 h EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
6.6 h EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5.8 h EXPERIMENT https://link.springer.com/article/10.2165/00137696-200402020-00005	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	LINSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% EXPERIMENT https://www.sciencedirect.com/science/article/pii/B9780128012383967114			ISOSORBIDE DINITRATE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
100% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3838399/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:		MOLSIDOMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	substrate 1193	substrate 1388

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741 MRP2 499 K+ channels 73 Ca2+ channels 59 ALDH2 21	ALDH2 21 CYP1A2 1197 CYP2A6 626 CYP2E1 729 CYP4A11 137	OCT1 39

Drug as perpetrator

Target	Modality	Activity
ALDH2 21	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/15331769/	no
K+ channels 73	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/abs/pii/S001429990800616X Page: abstract	no
Ca2+ channels 62	inhibitor 4027 Sources: https://link.springer.com/article/10.1007/BF00497774 Page: abstract	yes
MRP2 625	inhibitor 4027 Sources: https://www.ingentaconnect.com/content/ben/dml/2011/00000005/00000001/art00009 Page: abstract	yes
OCT1 656	inducer 1966 Sources: https://www.sciencedirect.com/science/article/abs/pii/S1056871913002578 Page: abstract	yes
P-gp 1932	inhibitor 4027 Sources: https://www.nature.com/articles/aps201225 Page: abstract	yes

Drug as victim

Target	Modality	Activity
CYP3A4 1946	substrate 4014 Sources: https://febs.onlinelibrary.wiley.com/doi/full/10.1016/S0014-5793%2899%2900612-2	major
CYP1A2 1197	substrate 4014 Sources: https://febs.onlinelibrary.wiley.com/doi/full/10.1016/S0014-5793%2899%2900612-2	minor
CYP2A6 626	substrate 4014 Sources: https://febs.onlinelibrary.wiley.com/doi/full/10.1016/S0014-5793%2899%2900612-2	minor
CYP2C9 1193	substrate 4014 Sources: https://febs.onlinelibrary.wiley.com/doi/full/10.1016/S0014-5793%2899%2900612-2	minor
CYP2D6 1388	substrate 4014 Sources: https://febs.onlinelibrary.wiley.com/doi/full/10.1016/S0014-5793%2899%2900612-2	minor
CYP2E1 729	substrate 4014 Sources: https://febs.onlinelibrary.wiley.com/doi/full/10.1016/S0014-5793%2899%2900612-2	minor
CYP4A11 137	substrate 4014 Sources: https://febs.onlinelibrary.wiley.com/doi/full/10.1016/S0014-5793%2899%2900612-2	minor
ALDH2 21	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15331769/	no

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:6061	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6061
ChemicalBook	CB2226929	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2226929
eMolecules	30154680	https://www.emolecules.com/cgi-bin/more?vid=30154680
eMolecules	33507015	https://www.emolecules.com/cgi-bin/more?vid=33507015
eMolecules	36753592	https://www.emolecules.com/cgi-bin/more?vid=36753592
eMolecules	524496	https://www.emolecules.com/cgi-bin/more?vid=524496
ZINC	ZINC000018089317	http://zinc15.docking.org/substances/ZINC000018089317
ChEBI	CHEBI:6062	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6062
ChemicalBook	CB3256697	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3256697
eMolecules	30488208	https://www.emolecules.com/cgi-bin/more?vid=30488208
eMolecules	713614	https://www.emolecules.com/cgi-bin/more?vid=713614
MolPort	MolPort-003-848-286	https://www.molport.com/shop/molecule-link/MolPort-003-848-286
ZINC	ZINC000001849548	http://zinc15.docking.org/substances/ZINC000001849548
ChEBI	CHEBI:28787	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28787
ChemicalBook	CB2145318	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2145318
ZINC	ZINC000008214625	http://zinc15.docking.org/substances/ZINC000008214625
AA Blocks	AA00ILEO	https://www.aablocks.com/goods/Goods/detail?id=AA00ILEO
Aaron Chemicals	AR00IM6G	http://www.aaronchem.com/1302-78-9
Alfa Chemistry	7077-34-1	https://www.alfa-chemistry.com/cas_7077-34-1.htm
Ambinter	Amb17672903	http://www.ambinter.com/reference/17672903
BioSynth	W-111015	https://www.biosynth.com/en/products/chemical-intermediates/basic-intermediates/products/W-111015.html
Chemspace	CSSB00016996527	https://chem-space.com/CSSB00016996527
Clearsynth	CS-O-00951	http://www.clearsynth.com/en/CSO00951.html
Lab Network	LN02049364	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN02049364
Oakwood	94458	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=79632&ExtHyperLink=1
Smolecule	S585822	https://www.smolecule.com/products/s585822
THE BioTek	bt-433598	https://www.thebiotek.com/product/others/bt-433598
ChEBI	CHEBI:7596	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7596
eMolecules	10397191	https://www.emolecules.com/cgi-bin/more?vid=10397191
3B Scientific (Wuhan) Corp	3B2-4956	http://www.3bsc.com/index/pro_info.php?id=79896
3B Scientific (Wuhan) Corp	3B3-046180	http://www.3bsc.com/index/pro_info.php?id=82779
ABI Chem	AC1L1MPG
ABI Chem	AC1Q21X4
AHH Chemical co.,ltd	MT-57727	http://www.ahhchemical.com/product/MT-57727.html
AN PharmaTech	AN-23936
Chemhere	Achem162548
Chemieliva Pharmaceutical Co., Ltd	PBCM0000174
ChemMol	49416736	http://www.chemmol.com/chemmol/49416736.html
ChemMol	99151477	http://www.chemmol.com/chemmol/99151477.html
Compound Cloud	6518
Hangzhou Yuhao Chemical Technology	LL0106
LGC Standards	DRE-LA15589000AL	https://www.lgcstandards.com/US/en/p/DRE-LA15589000AL
NovoSeek	6518
SelectLab Chemicals GmbH	Ex187
Sigma-Aldrich	ERP-109S_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/erp109s?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	P-037_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/p037?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma Aldrich	ERP-109S
Sigma Aldrich	P-037
Smolecule	S567259	https://www.smolecule.com/products/s567259
Tetrahedron	TS61261
Yick-Vic Chemicals & Pharmaceuticals (HK) Ltd.	PH-0472
Yuhao Chemical	LL0106	http://www.chemyuhao.com/78-11-5.html
ZINC	ZINC000008101167	http://zinc15.docking.org/substances/ZINC000008101167

PubMed

Title	Date	PubMed
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.	2007-07-15	17384201
Compromised aortic vasoreactivity in male estrogen receptor-alpha-deficient mice during acute lipopolysaccharide-induced inflammation.	2007-03	17158209
Melittin inhibits inflammatory target gene expression and mediator generation via interaction with IkappaB kinase.	2007-01-15	17067557
Ablation of NK1 receptor bearing neurons in the nucleus of the solitary tract blunts cardiovascular reflexes in awake rats.	2006-11-13	16982039
S-nitrosylation of Bcl-2 inhibits its ubiquitin-proteasomal degradation. A novel antiapoptotic mechanism that suppresses apoptosis.	2006-11-10	16980304
Inhibitors of inducible nitric oxide (NO) synthase are more effective than an NO donor in reducing carbon-tetrachloride induced acute liver injury.	2006-11	16874658
JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells.	2006-10	16439016
Acrylamide analog as a novel nitric oxide-independent soluble guanylyl cyclase activator.	2006-10	17050951
Cytotoxicity of nitric oxide is alleviated by zinc-mediated expression of antioxidant genes.	2006-10	17018880
Phenotype-dependent susceptibility of cholinergic neuroblastoma cells to neurotoxic inputs.	2006-09	16724269
NMDA receptor-nitric oxide transmission mediates neuronal iron homeostasis via the GTPase Dexras1.	2006-08-17	16908409
Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo.	2006-07-13	16821795
The cGMP/protein kinase G pathway contributes to dihydropyridine-sensitive calcium response and cytokine production in TH2 lymphocytes.	2006-05-05	16533816
Iron released by sodium nitroprusside contributes to heme oxygenase-1 induction via the cAMP-protein kinase A-mitogen-activated protein kinase pathway in RAW 264.7 cells.	2006-05	16439612
Labetalol pretreatment reduces blood pressure instability during surgical resection of pheochromocytoma.	2006-03	16520833
Effect of nitric oxide on mitogen-activated protein kinases in neonatal pulmonary vascular smooth muscle.	2006-01-05	16389725
Hypoxia-mimetic agents desferrioxamine and cobalt chloride induce leukemic cell apoptosis through different hypoxia-inducible factor-1alpha independent mechanisms.	2006-01	16374551
Involvement of nitric oxide pathways in short term modulation of tyrosine hydroxylase activity by endothelins 1 and 3 in the rat anterior hypothalamus.	2005-09-02	16023617
Nitric oxide induces oral squamous cell carcinoma cells apoptosis with p53 accumulation.	2005-09	15979383
Bax translocates from cytosol to mitochondria in cardiac cells during apoptosis: development of a GFP-Bax-stable H9c2 cell line for apoptosis analysis.	2005-07	15961378
Effects of sodium nitroprusside, a nitric oxide donor, on gamma-aminobutyric acid concentration in the brain and on picrotoxin-induced convulsions in combination with phenobarbitone in rats.	2005-03	15740777
Effect of nitric oxide on mitochondrial respiratory activity of human articular chondrocytes.	2005-03	15708893
Intracavernous sodium nitroprusside (SNP) versus papaverine/phentolamine in erectile dysfunction: a comparative study of short-term efficacy and side-effects.	2005-01	16422914
Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition.	2005-01	15306635
Ferulic acid inhibits endothelial cell proliferation through NO down-regulating ERK1/2 pathway.	2004-12-15	15486966
Sympathetic nerve activity in response to hypotensive stress in the postural tachycardia syndrome.	2004-11-16	15533861
The inhibitory effect of sodium nitroprusside on HIF-1 activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway.	2004-11-05	15465035
Regulation of cytoplasmic stress granules by apoptosis-inducing factor.	2004-09-01	15316071
Diminished baroreflex control of heart rate responses in otoconia-deficient C57BL/6JEi head tilt mice.	2004-08	15059776
Intrapericardial delivery enhances cardiac effects of sotalol and atenolol.	2004-07	15175557
Effects of TNF-alpha and IFN-gamma on nitric oxide-induced neurotoxicity in the mouse brain.	2004-06-01	15153526
Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation.	2004-06	15210857
Additive antinociceptive effect of the combination of diazoxide, an activator of ATP-sensitive K+ channels, and sodium nitroprusside and dibutyryl-cGMP.	2004-04-05	15063156
Esmolol attenuates hepatic blood flow responses during sodium nitroprusside-induced hypotension in dogs.	2004-04	15064263
Nitric oxide donor sodium nitroprusside dilates rat small arteries by activation of inward rectifier potassium channels.	2004-04	14993195
JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits Hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways.	2003-12	14566972
JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.	2003-04	12700285
The secondary amine/nitric oxide complex ion R(2)N[N(O)NO](-) as nucleophile and leaving group in S9N)Ar reactions.	2001-05-04	11325274
Temporary blindness due to sodium nitroprusside overdosage in a postoperative patient: an unusual adverse effect.	1992-06	1628477
The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog.	1992-06	1602014
Baroreflex changes produced by serotonergic or catecholaminergic lesions in the rat nucleus tractus solitarius.	1992-04	1560369
Effect of N omega-nitro-L-arginine methyl ester on arterial pressure and on vasodilator and vasoconstrictor responses: influence of initial vascular tone.	1992-03-03	1601062
Comparative cardiovascular effects of SNP, ATP and phentolamine during norepinephrine-induced hypertension in dogs.	1991-10	15278610
Rat renal papillary release of hypotensive substances in vitro.	1991-08	1655886
Blood pressure, pulse, and neurohumoral responses to nitroprusside-induced hypotension in normotensive aging men.	1991-07	1677019
Effects of fenoldopam on renal blood flow and systemic hemodynamics during isoflurane anesthesia.	1991-02	1678284
ACTH and vasopressin responses to insulin-induced hypoglycemia in intact and neurohypophysectomized conscious dogs.	1991-01	1646414
Features of the acute hypotensive action of carvedilol and its ameliorating effect on myocardial ischemia.	1991	1721975
Positive inotropy contributes to the hemodynamic mechanism of action of flosequinan (BTS 49465) in the intact dog.	1990-06	1694912
Venodilator effects of adenosine triphosphate and sodium nitroprusside; comparisons during controlled hypotension.	1987-09-01	15235850

Patents

Sample Use Guides

In Vivo Use Guide

mice were treated three times a week for 3 weeks with intravenous tail vein injections of either vehicle (2.25% Pluronic P123 in PBS) or JS-K (6 μmol/kg in the vehicle).

Route of Administration: Intravenous

In Vitro Use Guide

Human U87 cells (HTB-14), fibroblasts (CRL-1634), and astrocytes (CRL-8621; ATCC) were cultured in Dulbecco’s Minimal Essential Eagle Medium (DMEM; Gibco, USA) supplemented with 10% fetal calf serum (FCS) and penicillin (100U/mL)/streptomycin (100mg/mL) under normoxic conditions (95% air, 5% CO2, and 37°C). The nitric oxide donor JS-K (O2-(2.4-dinitrophenyl) 1-[(4-ethoxycarbonyl) piperazin-1-yl] diazen-1-ium1,2-diolate, CAS 7054 32-12-8) was dissolved in 100% dimethyl sulfoxide (DMSO) in a concentration of 5.2mM. U87 was incubated with JS-K doses of 0–15µM for 4 h. The JS-K solvent control (DMSO≤1%) was adjusted to the highest JS-K concentration used in these experiments. A cesium source emitting γ-radiation was used for radiotherapy (RT; 3×2Gy) with a 24-h interval between each RT dose (Isotopen Diagnostik CIS, Germany).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:12:55 GMT 2025` Edited by `admin` on `Mon Mar 31 18:12:55 GMT 2025`
Record UNII	31C4KY9ESH
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AMIDOGEN, OXO-

Preferred Name

English

NITRIC OXIDE

Official Name

English

NITROGEN(II) OXIDE

Systematic Name

English

NITROGEN OXIDE

Systematic Name

English

NITRIC OXIDE [MART.]

Common Name

English

NITROSYL RADICAL

Common Name

English

NITRIC OXIDE [HSDB]

Common Name

English

NITRIC OXIDE [EMA EPAR]

Common Name

English

OHM-11771

Code

English

INOVENT

Brand Name

English

NITRIC OXIDE [JAN]

Common Name

English

NITRIC OXIDE [EP MONOGRAPH]

Common Name

English

Nitric oxide [WHO-DD]

Common Name

English

NITRIC OXIDE [MI]

Common Name

English

NITRIC OXIDE [ORANGE BOOK]

Common Name

English

NITRIC OXIDE [VANDF]

Common Name

English

GENOSYL

Brand Name

English

NITRIC OXIDE TRIMER

Common Name

English

NITRIC OXIDE [USAN]

Common Name

English

INOMAX

Brand Name

English

Nitrogen monoxide

Systematic Name

English

NITROGEN OXIDE (NO)

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

603917